Shares of the drugmaker have appreciated by 12.35% over the course of the past month, outperforming the Medical sector's gain of 2.46% and the S&P 500's gain of 3.11%. For the full year, the Zacks Consensus Estimates project earnings of $17.06 per share and a revenue of $10.72 billion, demonstrating changes of +12.02% and +8.6%, respectively, from the preceding year. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capit ...